Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Breast carcinomas are often infiltrated by inflammatory cells, particularly macrophages and T lymphocytes, but the significance of these cells remains unclear. One possible role of these inflammatory cells is that they represent a cell-mediated immune response against the carcinoma. CD8+lymphocytes are a known crucial component of cell-mediated immunity. The purpose of this study was to explore the prognostic value of tumor-infiltrating CD8+cytotoxic lymphocytes in breast cancer. Tumor-infiltrating CD8+lymphocytes were assessed by immunohistochemical staining of tissue microarray cores from 1,334 unselected breast tumors from patients with long-term follow-up. The number of CD8+T cells was counted in tumor nests (intratumoral), in stroma adjacent to tumor cells, and in stroma distant to tumor cells, and their relationship with clinical outcome was determined. The total number of CD8+cells was positively correlated with tumor grade (r s= 0.20; P < .001) and inversely correlated with patient's age at diagnosis, estrogen receptor–alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P < .001). The total patient cohort was randomly divided into two separate training and validation sets before performing univariate survival analysis. Total number and distant stromal CD8+lymphocytes were associated with better patient survival (P = .041 and P < .001, respectively) in the training set. In multivariate analysis, total CD8+T-cell count was an independent prognostic factor in both training and validation sets. These results suggest that tumor-infiltrating CD8+T lymphocytes have antitumor activity as judged by their favorable effect on patients' survival and could potentially be exploited in the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Cited by
Items 101–126 of 126
The immune network in pancreatic cancer development and progression
Wörmann, S. M., Diakopoulos, K. N., Lesina, M., & Algül, H. (2014) · Oncogene · doi:10.1038/onc.2013.257 · Cited by 205
Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective
Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V., & Mandruzzato, S. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318242169f · Cited by 202
“Another example is the presence of tumor-infiltrating lymphocytes, which have been shown to be of prognostic relevance in different solid tumors.(58,59) MDSCs are clearly an important mechanism of immune evasion by tumors, but thus far there is an overall paucity of studies that have explored in detail the overall pro…”
BackgroundMulti-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan, Z., Ding, Y., Kim, J., Jung, H. H., Chung, W., Lal, S., Cho, S., Fernandez-Banet, J., Lee, S. K., Kim, S. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04129-4 · Cited by 202
The breast tumor microenvironment: role in cancer development, progression and response to therapy
Mittal, S., Brown, N. J., & Holen, I. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1439382 · Cited by 201
“TIL count has also been linked with better survival in patients with ER-negative tumors [31,36].”
BackgroundCancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 197
Corrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
“Clin Cancer Res; 21(21) November 1, 2015 Clinical Cancer Research 4776”
BackgroundInfluentialInteractions between immunity, proliferation and molecular subtype in breast cancer prognosis
Nagalla, S., Chou, J. W., Willingham, M. C., Ruiz, J., Vaughn, J. P., Dubey, P., Lash, T. L., Hamilton-Dutoit, S. J., Bergh, J., Sotiriou, C., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r34 · Cited by 196
“These observations support the view that cancer-leukocyte interactions in the microenvironment of established tumors may function to limit the growth and metastatic progression of breast cancer [20-22].”
BackgroundTekpli, X., Lien, T., Røssevold, A. H., Nebdal, D., Borgen, E., Ohnstad, H. O., Kyte, J. A., Vallon-Christersson, J., Fongaard, M., Due, E. U., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13329-5 · Cited by 192
Wolf, G. T., Chepeha, D. B., Bellile, E., Nguyen, A., Thomas, D., & McHugh, J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.09.006 · Cited by 190
“In particular, the CD8 subset which has been shown to be important in breast and colon cancers [8] only showed a borderline significantly higher mean level in patients who recurred even though CD8 counts added some prognostication when the important clinical variable extracapsular nodal extension was examined.”
BackgroundGyőrffy, B., Bottai, G., Fleischer, T., Munkácsy, G., Budczies, J., Paladini, L., Børresen-Dale, A.-L., Kristensen, V. N., & Santarpia, L. (2016) · International Journal of Cancer · doi:10.1002/ijc.29684 · Cited by 182
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Emens, L. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.147 · Cited by 172
T lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
Klauschen, F., Müller, K.-R., Binder, A., Bockmayr, M., Hägele, M., Seegerer, P., Wienert, S., Pruneri, G., de Maria, S., Badve, S., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.001 · Cited by 168
Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer
Zhang, D., He, W., Wu, C., Tan, Y., He, Y., Xu, B., Chen, L., Li, Q., & Jiang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00071 · Cited by 164
D’Amico, L., Mahajan, S., Capietto, A.-H., Yang, Z., Zamani, A., Ricci, B., Bumpass, D. B., Meyer, M., Su, X., Wang-Gillam, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150950 · Cited by 160
“Cytotoxic T cells are central players in immune-mediated control of cancer, and the extent of tumor infiltration by cytotoxic T cells correlates with a favorable prognosis (Galon et al., 2006; Hamanishi et al., 2007; Mahmoud et al., 2011; Bindea et al., 2013).”
BackgroundSong, I. H., Heo, S.-H., Bang, W. S., Park, H. S., Park, I. A., Kim, Y.-A., Park, S. Y., Roh, J., Gong, G., & Lee, H. J. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.215 · Cited by 143
Wang, K., Shen, T., Siegal, G. P., & Wei, S. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.012 · Cited by 123
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
Amgad, M., Hodge, J. M., Elsebaie, M. A. T., Bodelon, C., Puvanesarajah, S., Gutman, D. A., Siziopikou, K. P., Goldstein, J. A., Gaudet, M. M., Teras, L. R., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02643-7 · Cited by 137
Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers · doi:10.3390/cancers11050714 · Cited by 103
PRKCI promotes immune suppression in ovarian cancer
Sarkar, S., Bristow, C. A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S. Y., et al. (2017) · Genes & Development · doi:10.1101/gad.296640.117 · Cited by 93
“Since spontaneous T-cell infiltration in solid cancers has been found to associate with a favorable clinical outcome (Zhang et al. 2003; Curiel et al. 2004; Kreike et al. 2007;Mahmoud et al. 2011; Rusakiewicz et al. 2013), high PRKCI expression would be predicted to be associated with poor survival.”
BackgroundLocal iron homeostasis in the breast ductal carcinoma microenvironment
Marques, O., Porto, G., Rêma, A., Faria, F., Cruz Paula, A., Gomez-Lazaro, M., Silva, P., Martins da Silva, B., & Lopes, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2228-y · Cited by 90
Koh, J., Kim, S., Kim, M.-Y., Go, H., Jeon, Y. K., & Chung, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14632 · Cited by 77
Liu, S., Chen, B., Burugu, S., Leung, S., Gao, D., Virk, S., Kos, Z., Parulekar, W. R., Shepherd, L., Gelmon, K. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2085 · Cited by 57
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Wang, L., Miyahira, A. K., Simons, D. L., Lu, X., Chang, A. Y., Wang, C., Suni, M. A., Maino, V. C., Dirbas, F. M., Yim, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1373 · Cited by 55
Jian, C., Wu, T., Wang, L., Gao, C., Fu, Z., Zhang, Q., & Shi, C. (2024) · Small · doi:10.1002/smll.202309279 · Cited by 33
Malczewski, A. B., Ketheesan, N., Coward, J. I. G., & Navarro, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624434 · Cited by 22
Metadata
- Authors
- Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15
- Pages
- 1949-1955
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120338564
- Cited by
- 1,367
- References
- 50
- FWCI
- 20.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.